A Safety and Tolerability Study of Denufosol in 2-4 Year Olds

NCT01181622 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: denufosol tetrasodium Inhalation Solution
DRUG: 0.9% w/v sodium chloride solution

Sponsor

Merck Sharp & Dohme LLC